Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination with either Bortezomib or Daratumumab in Patients with Relapsed or Relapsed-Refractory Multiple Myeloma.

Trial Profile

An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination with either Bortezomib or Daratumumab in Patients with Relapsed or Relapsed-Refractory Multiple Myeloma.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Melphalan flufenamide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ANCHOR
  • Sponsors Oncopeptides
  • Most Recent Events

    • 04 Dec 2018 Preliminary results (Data cut off 18 July 2018, n=8) of phase I part, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 02 Dec 2018 Results (cut-off data till November 12, 2018) presented in the Oncopeptides Media Release
    • 02 Dec 2018 According to an Oncopeptides media release, data from this trial were presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition on 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top